SK282437B6 - Tepelne stála kryštalická modifikácia N-metyl-N-[(1S)-1-fenyl- 2-((3S)-3-hydroxypyrolidin-1-yl)etyl]-2,2- difenylacetamidhydrochloridu a spôsob jej prípravy - Google Patents

Tepelne stála kryštalická modifikácia N-metyl-N-[(1S)-1-fenyl- 2-((3S)-3-hydroxypyrolidin-1-yl)etyl]-2,2- difenylacetamidhydrochloridu a spôsob jej prípravy Download PDF

Info

Publication number: SK282437B6
Authority: SK; Slovakia
Prior art keywords: hydroxypyrrolidin; phenyl; ethyl; methyl; solvent
Prior art date: 1995-08-26

Application number

SK1089-96A

Other languages

English (en)

Slovak (sk)

Other versions

SK108996A3 (en

Inventor

Inge Stein

Holger Beeres

Klaus Beschmann

Steffen Neuenfeld

Andrew Barber

Original Assignee

Merck Patent Gesellschaft Mit Beschr�Nkter Haftung

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-26

Filing date

1996-08-22

Publication date

2002-02-05

1996-08-22 Application filed by Merck Patent Gesellschaft Mit Beschr�Nkter Haftung filed Critical Merck Patent Gesellschaft Mit Beschr�Nkter Haftung

1997-06-04 Publication of SK108996A3 publication Critical patent/SK108996A3/sk

2002-02-05 Publication of SK282437B6 publication Critical patent/SK282437B6/sk

Links

230000004048 modification Effects 0.000 title claims abstract description 21
238000012986 modification Methods 0.000 title claims abstract description 21
238000002360 preparation method Methods 0.000 title claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title description 4
239000002904 solvent Substances 0.000 claims abstract description 20
GMJSLABTEURMBF-CLSOAGJSSA-N n-[(1s)-2-[(3s)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-n-methyl-2,2-diphenylacetamide;hydrochloride Chemical compound Cl.C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 GMJSLABTEURMBF-CLSOAGJSSA-N 0.000 claims abstract description 13
MSYLETHDEIJMAF-UHFFFAOYSA-N 2,2-diphenylacetyl chloride Chemical compound C=1C=CC=CC=1C(C(=O)Cl)C1=CC=CC=C1 MSYLETHDEIJMAF-UHFFFAOYSA-N 0.000 claims abstract description 12
238000006243 chemical reaction Methods 0.000 claims abstract description 12
239000012043 crude product Substances 0.000 claims abstract description 6
238000002844 melting Methods 0.000 claims description 15
230000008018 melting Effects 0.000 claims description 15
238000000034 method Methods 0.000 claims description 12
230000008569 process Effects 0.000 claims description 8
239000004480 active ingredient Substances 0.000 abstract description 18
239000008194 pharmaceutical composition Substances 0.000 abstract description 13
208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 7
150000003839 salts Chemical class 0.000 abstract description 6
206010065390 Inflammatory pain Diseases 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 description 36
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
239000003814 drug Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
208000002193 Pain Diseases 0.000 description 7
239000003826 tablet Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
239000007858 starting material Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
238000003860 storage Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
-1 (3S) -3-hydroxypyrrolidin-1-yl Chemical group 0.000 description 4
230000009471 action Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
208000025747 Rheumatic disease Diseases 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
238000001816 cooling Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
238000000113 differential scanning calorimetry Methods 0.000 description 3
239000012154 double-distilled water Substances 0.000 description 3
210000003405 ileum Anatomy 0.000 description 3
230000008533 pain sensitivity Effects 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
208000008035 Back Pain Diseases 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
208000004454 Hyperalgesia Diseases 0.000 description 2
208000035154 Hyperesthesia Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
201000009053 Neurodermatitis Diseases 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
206010042496 Sunburn Diseases 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000007803 itching Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000008347 soybean phospholipid Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000007704 transition Effects 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
SUPNUNXTOMHOHP-UHFFFAOYSA-N 2,2-diphenylacetamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C(=O)N)C1=CC=CC=C1 SUPNUNXTOMHOHP-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010012434 Dermatitis allergic Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000019430 Motor disease Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000012084 abdominal surgery Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
102000048260 kappa Opioid Receptors Human genes 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012264 purified product Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
108020001588 κ-opioid receptors Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

SK1089-96A 1995-08-26 1996-08-22 Tepelne stála kryštalická modifikácia N-metyl-N-[(1S)-1-fenyl- 2-((3S)-3-hydroxypyrolidin-1-yl)etyl]-2,2- difenylacetamidhydrochloridu a spôsob jej prípravy SK282437B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19531464A DE19531464A1 (de)	1995-08-26	1995-08-26	N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid

Publications (2)

Publication Number	Publication Date
SK108996A3 SK108996A3 (en)	1997-06-04
SK282437B6 true SK282437B6 (sk)	2002-02-05

Family

ID=7770485

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1089-96A SK282437B6 (sk)	1995-08-26	1996-08-22	Tepelne stála kryštalická modifikácia N-metyl-N-[(1S)-1-fenyl- 2-((3S)-3-hydroxypyrolidin-1-yl)etyl]-2,2- difenylacetamidhydrochloridu a spôsob jej prípravy

Country Status (25)

Country	Link
US (1)	US6060504A (cs)
EP (1)	EP0761650B1 (cs)
JP (3)	JP5023273B2 (cs)
KR (1)	KR100436254B1 (cs)
CN (1)	CN1081631C (cs)
AR (1)	AR004679A1 (cs)
AT (1)	ATE207895T1 (cs)
AU (1)	AU716615B2 (cs)
BR (1)	BR9603540A (cs)
CA (1)	CA2184049C (cs)
CZ (1)	CZ287783B6 (cs)
DE (2)	DE19531464A1 (cs)
DK (1)	DK0761650T3 (cs)
ES (1)	ES2165948T3 (cs)
HU (1)	HU226667B1 (cs)
MX (1)	MX9603606A (cs)
NO (1)	NO307048B1 (cs)
PL (1)	PL187691B1 (cs)
PT (1)	PT761650E (cs)
RU (1)	RU2174976C2 (cs)
SI (1)	SI0761650T1 (cs)
SK (1)	SK282437B6 (cs)
TW (1)	TW513407B (cs)
UA (1)	UA41978C2 (cs)
ZA (1)	ZA967200B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1828399A (en) *	1997-12-22	1999-07-12	Alza Corporation	Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) *	1998-04-20	1999-10-21	Merck Patent Gmbh	Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain
DE10116978A1 (de) *	2001-04-05	2002-10-10	Merck Patent Gmbh	Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
WO2003097051A2 (en) *	2002-05-17	2003-11-27	Merck Patent Gmbh	Use of compounds that are effective as selective opiate receptor modulators
DE10259245A1 (de) *	2002-12-17	2004-07-01	Merck Patent Gmbh	Derivate des Asimadolins mit kovalent gebundenen Säuren
EP1680115A1 (en) *	2003-10-30	2006-07-19	Tioga Pharmaceuticals, Inc.	Use of selective opiate receptor modulators in the treatment of neuropathy
CA2682608A1 (en)	2007-03-30	2008-10-09	Tioga Pharmaceuticals, Inc.	Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
EP2284987B1 (en) *	2009-08-12	2019-02-06	Braun GmbH	Method and device for adjusting the frequency of a drive current of an electric motor
NZ602872A (en) *	2010-04-07	2014-05-30	Onyx Therapeutics Inc	Crystalline peptide epoxyketone immunoproteasome inhibitor
US9675587B2 (en)	2013-03-14	2017-06-13	Allergan Holdings Unlimited Company	Opioid receptor modulator dosage formulations
CN103664727A (zh) *	2013-12-19	2014-03-26	无锡万全医药技术有限公司	一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
ES2906979T3 (es)	2016-12-21	2022-04-21	Tioga Pharmaceuticals Inc	Formulaciones farmacéuticas sólidas de asimadolina
EP3932390A1 (en)	2020-07-02	2022-01-05	Dr. August Wolff GmbH & Co. KG Arzneimittel	Topical gel formulation containing asimadoline

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8205135D0 (sv) *	1982-09-09	1982-09-09	Astra Laekemedel Ab	Benzamido-derivatives
DE4034785A1 (de) *	1990-11-02	1992-05-07	Merck Patent Gmbh	1-(2-arylethyl)-pyrrolidine
DE4215213A1 (de) *	1992-05-09	1993-11-11	Merck Patent Gmbh	Arylacetamide

1995
- 1995-08-26 DE DE19531464A patent/DE19531464A1/de not_active Withdrawn
1996
- 1996-08-02 EP EP96112489A patent/EP0761650B1/de not_active Expired - Lifetime
- 1996-08-02 SI SI9630392T patent/SI0761650T1/xx unknown
- 1996-08-02 DK DK96112489T patent/DK0761650T3/da active
- 1996-08-02 PT PT96112489T patent/PT761650E/pt unknown
- 1996-08-02 ES ES96112489T patent/ES2165948T3/es not_active Expired - Lifetime
- 1996-08-02 AT AT96112489T patent/ATE207895T1/de active
- 1996-08-02 DE DE59608050T patent/DE59608050D1/de not_active Expired - Lifetime
- 1996-08-16 CZ CZ19962434A patent/CZ287783B6/cs not_active IP Right Cessation
- 1996-08-19 AU AU62149/96A patent/AU716615B2/en not_active Ceased
- 1996-08-21 UA UA96083322A patent/UA41978C2/uk unknown
- 1996-08-22 JP JP22129696A patent/JP5023273B2/ja not_active Expired - Fee Related
- 1996-08-22 SK SK1089-96A patent/SK282437B6/sk not_active IP Right Cessation
- 1996-08-23 TW TW085110305A patent/TW513407B/zh not_active IP Right Cessation
- 1996-08-23 CA CA002184049A patent/CA2184049C/en not_active Expired - Fee Related
- 1996-08-23 CN CN96111404A patent/CN1081631C/zh not_active Expired - Fee Related
- 1996-08-23 AR ARP960104088A patent/AR004679A1/es not_active Application Discontinuation
- 1996-08-23 RU RU96116925/04A patent/RU2174976C2/ru not_active IP Right Cessation
- 1996-08-23 NO NO963526A patent/NO307048B1/no not_active IP Right Cessation
- 1996-08-23 PL PL96315799A patent/PL187691B1/pl not_active IP Right Cessation
- 1996-08-23 MX MX9603606A patent/MX9603606A/es unknown
- 1996-08-23 ZA ZA967200A patent/ZA967200B/xx unknown
- 1996-08-23 BR BR9603540A patent/BR9603540A/pt active Search and Examination
- 1996-08-24 KR KR1019960035289A patent/KR100436254B1/ko not_active Expired - Fee Related
- 1996-08-26 HU HU9602346A patent/HU226667B1/hu not_active IP Right Cessation
- 1996-08-26 US US08/703,350 patent/US6060504A/en not_active Expired - Lifetime
2008
- 2008-10-02 JP JP2008257423A patent/JP2009046501A/ja active Pending
2012
- 2012-09-18 JP JP2012204622A patent/JP2012246321A/ja active Pending

Also Published As

Publication number	Publication date
DE19531464A1 (de)	1997-02-27
NO307048B1 (no)	2000-01-31
TW513407B (en)	2002-12-11
NO963526D0 (no)	1996-08-23
SK108996A3 (en)	1997-06-04
CZ243496A3 (en)	1997-03-12
NO963526L (no)	1997-02-27
PL315799A1 (en)	1997-03-03
HUP9602346A3 (en)	1998-01-28
JP2009046501A (ja)	2009-03-05
CZ287783B6 (en)	2001-02-14
JP5023273B2 (ja)	2012-09-12
SI0761650T1 (en)	2002-04-30
MX9603606A (es)	1997-03-29
EP0761650A1 (de)	1997-03-12
DK0761650T3 (da)	2002-02-18
EP0761650B1 (de)	2001-10-31
AU716615B2 (en)	2000-03-02
HUP9602346A2 (en)	1997-09-29
ATE207895T1 (de)	2001-11-15
AR004679A1 (es)	1999-03-10
AU6214996A (en)	1997-03-06
HU226667B1 (en)	2009-06-29
JP2012246321A (ja)	2012-12-13
KR100436254B1 (ko)	2005-01-25
CN1151986A (zh)	1997-06-18
JPH09110830A (ja)	1997-04-28
UA41978C2 (uk)	2001-10-15
CN1081631C (zh)	2002-03-27
BR9603540A (pt)	1998-05-12
ZA967200B (en)	1997-03-03
HU9602346D0 (en)	1996-10-28
PT761650E (pt)	2002-04-29
PL187691B1 (pl)	2004-09-30
US6060504A (en)	2000-05-09
KR970010744A (ko)	1997-03-27
ES2165948T3 (es)	2002-04-01
CA2184049A1 (en)	1997-02-27
CA2184049C (en)	2007-10-02
DE59608050D1 (de)	2001-12-06
RU2174976C2 (ru)	2001-10-20

Legal Events

Date	Code	Title	Description
2015-05-05	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20140822

Publication	Publication Date	Title
JP2009046501A (ja)	2009-03-05	Ｎ−メチル−ｎ−［（１ｓ）−１−フェニル−２−｛（３ｓ）−３−ヒドロキシピロリジン−１−イル｝エチル］−２，２−ジフェニルアセトアミド
JP4415075B2 (ja)	2010-02-17	炎症性腸疾患のためのカッパーアヘン製剤作働薬
AU653902B2 (en)	1994-10-13	6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1- carboxamide as an analgesic and anti-inflammatory agent
JP2010520176A (ja)	2010-06-10	５−（２，４−ジヒドロキシ−５−イソプロピル−フェニル）−４−（４−モルホリン−４−イルメチル−フェニル）−イソオキサゾール−３−カルボン酸エチルアミドの酸付加塩、水和物および多形、ならびにこれらの形態を含む製剤
HU193719B (en)	1987-11-30	Process for producing antiarrithmic aryloxy-6-/aminoalkyl/-1-pirrolidine- and piperidine-carboxylic acids
CN115850289B (zh)	2023-10-24	一种新型普拉洛芬衍生物及其药物组合物和用途
JPS6219577A (ja)	1987-01-28	新規なベンジルピペラジン誘導体および該化合物を有効成分とする医薬組成物
NO139733B (no)	1979-01-22	Analogifremgangsmaate for fremstilling av terapeutisk aktive derivater av metylamin
JPH02237928A (ja)	1990-09-20	置換ベンズアミドより成る胃の自動運動性増進用薬剤
CA2153050C (en)	1998-12-29	Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide
LT3598B (en)	1995-12-27	Tetrahydroisoquinolinylcarbamates of 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo£2,3-b\|indole
RU2045268C1 (ru)	1995-10-10	Противогистаминное и антиаллергическое средство и способ приготовления глутамината хинуклидил-3-дифенилкарбинола в виде раствора для инъекций
JPS6117832B2 (cs)	1986-05-09
BRPI0611096A2 (pt)	2010-12-21	(5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)a mino]-1,3-tiazol-4(5h)-ona
NO159587B (no)	1988-10-10	Fremgangsm te for fremstilling av 2-(parasubstituersy)-2-alkylpropionsyrederivater.
PL196363B1 (pl)	2007-12-31	Kłódka zatrzaskowa